Taxane mechanisms of action: Potential implications for treatment sequencing in metastatic castration-resistant prostate cancer

European Urology

Volumn 65, Issue 6, 2014, Pages 1198-1204

  Fitzpatrick, John M ^a   De Wit, Ronald ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Abiraterone; Cabazitaxel; Castration resistant prostate cancer; Docetaxel; Enzalutamide; Therapy sequence

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; PREDNISONE; ANDROGEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL NUCLEUS; CELL VIABILITY; CYTOPLASM; CYTOTOXICITY; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; GENE SILENCING; HORMONAL THERAPY; HUMAN; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG INTERACTION; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROGENS; ANDROSTENOLS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; HUMANS; MALE; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 84899575660     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.07.022     Document Type: Article

References (44)

1. I.F. Tannock, R. de Wit, and W.R. Berry et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
2. D.P. Petrylak, C.M. Tangen, and M.H. Hussain et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
3. J.S. de Bono, S. Oudard, and M. Ozguroglu et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
4. M.A. Jordan, and L. Wilson Microtubules as a target for anticancer drugs Nat Rev Cancer 4 2004 253 265
5. P.J. Moos, and F.A. Fitzpatrick Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits Cell Growth Differ 9 1998 687 697
6. Y. Li, X. Li, M. Hussain, and F.H. Sarkar Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray Neoplasia 6 2004 158 167
7. E. Komlodi-Pasztor, D. Sackett, J. Wilkerson, and T. Fojo Mitosis is not a key target of microtubule agents in patient tumors Nat Rev Clin Oncol 8 2011 244 250
8. M.S. Darshan, M.S. Loftus, and M. Thadani-Mulero et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer Cancer Res 71 2011 6019 6029
9. I. Brown, K. Shalli, and S.L. McDonald et al. Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells Breast Cancer Res 6 2004 R601 R607
10. L. Gan, J. Wang, H. Xu, and X. Yang Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling Prostate 71 2011 1158 1166
11. J.A. McCubrey, L.S. Steelman, and W.H. Chappell et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochim Biophys Acta 1773 2007 1263 1284
12. D.Z. Qian, B.L. Rademacher, and J. Pittsenbarger et al. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity Prostate 70 2010 433 442
13. M. Puhr, J. Hoefer, and G. Schafer et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205 Am J Pathol 181 2012 2188 2201
14. J. Ren, Y. Chen, H. Song, L. Chen, and R. Wang Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line J Cell Biochem 114 2013 1395 1403
15. D.B. Agus, C. Cordon-Cardo, and W. Fox et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence J Natl Cancer Inst 91 1999 1869 1876
16. B. Tombal What is the pathophysiology of a hormone-resistant prostate tumour? Eur J Cancer 47 2011 S179 S188
17. J.S. de Bono, C.J. Logothetis, and A. Molina et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
18. H.I. Scher, K. Fizazi, and F. Saad et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
19. M.L. Zhu, and N. Kyprianou Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells FASEB J 24 2010 769 777
20. Y. Sun, B.E. Wang, and K.G. Leong et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy Cancer Res 72 2012 527 536
21. K. Kuroda, H. Liu, and S. Kim et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy Prostate 69 2009 1579 1585
22. L. Gan, S. Chen, and Y. Wang et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer Cancer Res 69 2009 8386 8394
23. M.L. Zhu, C.M. Horbinski, and M. Garzotto et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Res 70 2010 7992 8002
24. L.E. Heisler, A. Evangelou, and A.M. Lew et al. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor Mol Cell Endocrinol 126 1997 59 73
25. R.B. Montgomery, M. Bonham, and P.S. Nelson et al. Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells Prostate 65 2005 141 150
26. I.V. Litvinov, D.J. Vander Griend, and L. Antony et al. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells Proc Natl Acad Sci U S A 103 2006 15085 15090
27. A.H. Reid, G. Attard, and D.C. Danila et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol 28 2010 1489 1495
28. J. Mezynski, C. Pezaro, and D. Bianchini et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23 2012 2943 2947
29. P.G. Febbo, J.P. Richie, and D.J. George et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer Clin Cancer Res 11 2005 5233 5240
30. G. Gravis, K. Fizazi, and F. Joly et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Lancet Oncol 14 2013 149 158
31. K. Fizazi, H.I. Scher, and A. Molina et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
32. K.N. Chi Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) [abstract 15] J Clin Oncol 2012 30
33. D. Mukherji, C.J. Pezaro, D. Bianchini, A. Zivi, and J.S. de Bono Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel [abstract 17] J Clin Oncol 30 Suppl 2012
34. Y. Loriot, D. Bianchini, and E. Ileana et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
35. K.L. Noonan, S. North, and R.L. Bitting et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 2013 1802 1807
36. S. Oudard, F. Mercier, and A. Flechon et al. Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies in metastatic castration-resistant prostate cancer (mCRPC) [abstract 137] J Clin Oncol 31 Suppl 6 2013
37. J.P. Pezaro, S. Le Moulec, and L. Albiges et al. Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate [abstract 155] J Clin Oncol 31 Suppl 6 2013
38. A. Angelergues, D. Maillet, and A. Flechon et al. Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: sequencing might matter [abstract 5063] J Clin Oncol 31 Suppl 2013
39. C.J. Ryan, M.R. Smith, and J.S. de Bono et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
40. D.E. Rathkopf, M.R. Smith, and J.S. De Bono et al. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy [abstract 5] J Clin Oncol 31 Suppl 6 2013
41. D. Azria, C. Massard, and D. Tosi et al. An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): predictive parameters of response [abstract 149] J Clin Oncol 30 Suppl 5 2012
42. Y. Loriot, C. Massard, and L. Albiges et al. Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity [abstract 213] J Clin Oncol 30 Suppl 5 2012
43. S. Oudard, J.S. De Bono, and M. Ozguroglu et al. Impact of cabazitaxel (Cbz) + prednisone (P; CbzP) on overall survival (OS) at 2 yrs and in patients (pts) with aggressive disease: post-hoc analyses of TROPIC trial [conference abstract] Ann Oncol 23 2012 ix307
44. R. van Soest, E. de Morrée, and L. Shen et al. The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: data from the TAX 327 study [abstract 44] J Clin Oncol 31 Suppl 6 2013